Drugs - Drugs Xagena

Drugs

Home Page

Xagena Medicine

Xagena.net

Bisphosphonates associated with osteonecrosis of the jaw

Nursing infants may be at increased risk of Morphine overdose if their mothers are taking Codeine

Heart failure risk: boxed warning for Actos and Avandia

Serious liver adverse reactions associated with use of Prexige

Australia: TGA cancels registration of Prexige because of serious liver side effects

Australia: urgent advice regarding management of patients taking Lumiracoxib

Selective COX-2 inhibitors linked to risk of myocardial infarction

Arava linked to peripheral neuropathy

Lumiracoxib linked to tisk of hepatotoxicity

Somatropin is not recommended as an antiaging therapy

ACAM2000, a second-generation smallpox vaccine, FDA approved

Postmenopausal women: Evista for reducing the risk of invasive breast cancer, FDA approved

QT prolongation and torsades de pointes linked to Halcion

Premature ejaculation is a frequent male sexual complaint

Overweight and obesity: contraindicated use of Meridia and cardiovascular adverse reactions

Cardiac surgery: Trasylol increases the risk for death compared to the other antifibrinolytic drugs

FDA: Lyrica for treatment of fibromyalgia

Schizophrenia: Clozapine associated with myocarditis

Antidepressants: Mirtazapine linked to blood dyscrasias

EMEA: Acomplia must not be used in patients on antidepressants or with major depression

Hot flushes: EMEA recommends withdrawal of medicinal products containing Veralipride

Asthma: risk of anaphylaxis following administration of Omalizumab

Restricted use of Zelnorm, a drug for irritable bowel syndrome with constipation and chronic idiopathic constipation

NICE: Adalimumab and Rituximab for the treatment of arthritis

EMEA has approved Aclasta as first once-yearly treatment for postmenopausal osteoporosis

Erectile dysfunction drugs linked to potential risk of sudden hearing loss

Antifibrinolytic drugs: FDA has requested marketing suspension of Trasylol

DPP-4 inhibitors: Novartis has improved Galvus risk/benefit profile

FDA has strengthened boxed warnings for erythropoiesis-stimulating agents

Inoperable hepatocellular carcinoma: FDA has approved Nexavar

Next Pages 1 2 3 [4] 5 6 7 8 9 10

Link

• Allergology

• Biomedicine

• Dermatology

• Diabetology

• Diagnostics

• Endocrinology

• Gastroenterology

• Gene Medicine

• Infectivology

• Ophthalmology

• Pharmacology

• Rheumatology

• Stem Therapy

n Xagena.it

Powered by Luca Malattia - LM Web Solutions